Department of Medicinal Chemistry and Natural Products, Institute of Drug Research, The Hebrew University of Jerusalem, Jerusalem 91120, Israel.
Chem Commun (Camb). 2010 Mar 21;46(11):1842-4. doi: 10.1039/b925721g. Epub 2010 Feb 12.
Reduction of anticancer prodrugs such as ctc-[PtCl(2)(CH(3)CO(2))(2)(NH(3))(Am)] can yield three products in addition to the expected cis-[PtCl(2)(NH(3))(Am)]. A possible explanation is that reduction proceeds by several pathways where in addition to the loss of two axial ligands, one axial (acetato) and one equatorial (chlorido) ligand, or two equatorial ligands are eliminated.
抗癌前药如 ctc-[PtCl(2)(CH(3)CO(2))(2)(NH(3))(Am)] 的还原除了生成预期的顺式-[PtCl(2)(NH(3))(Am)]外，还可以生成三种产物。一种可能的解释是，还原通过几种途径进行，除了失去两个轴向配体外，一个轴向（乙酰基）和一个赤道（氯）配体，或两个赤道配体被消除。
